Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model

Wai, Christine Y.Y.; Leung, Nicki Y.H.; Leung, Patrick S.C.; Chu, Ka Hou

doi:10.3390/ijms20184656

Cited by 15 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our first step, we cloned the tropomyosin hypoallergens, MEM49 or MED171, into the mammalian expression vector pCI-Neo to construct two DNA vaccine candidates (pMEM49 and pMED171; Figure 3). BALB/c mice with shrimp tropomyosin-induced hypersensitivity treated with pMEM49 or pMED171 had their allergic symptoms ameliorated significantly [95]. This was in line with the significant reduction in levels of specific IgE and expression of Th2 cytokines, as well as infiltration of inflammatory cells in the small intestine (i.e., mast cells and eosinophils).…”

Section: Dna Vaccinesupporting

confidence: 60%

Overcoming Shellfish Allergy: How Far Have We Come?

Wai

Leung

Chu

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Shellfish allergy caused by undesirable immunological responses upon ingestion of crustaceans and mollusks is a common cause of food allergy, especially in the Asia-Pacific region. While the prevalence of shellfish allergy is increasing, the mainstay of clinical diagnosis for these patients includes extract-based skin prick test and specific IgE measurement while clinical management consists of food avoidance and as-needed use of adrenaline autoinjector should they develop severe allergic reactions. Such a standard of care is unsatisfactory to both patients and healthcare practitioners. There is a pressing need to introduce more specific diagnostic methods, as well as effective and safe therapies for patients with shellfish allergy. Knowledge gained on the identifications and defining the immuno-molecular features of different shellfish allergens over the past two decades have gradually translated into the design of new diagnostic and treatment options for shellfish allergy. In this review, we will discuss the epidemiology, the molecular identification of shellfish allergens, recent progress in various diagnostic methods, as well as current development in immunotherapeutic approaches including the use of unmodified allergens, hypoallergens, immunoregulatory peptides and DNA vaccines for the prevention and treatment of shellfish allergy. The prospect of a “cure “for shellfish allergy is within reach.

show abstract

Section: Dna Vaccinesupporting

confidence: 60%

Overcoming Shellfish Allergy: How Far Have We Come?

Wai

Leung

Chu

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…DNA vaccine-based immunotherapy is another emerging trend in the treatment of allergies. Our group thus focused on investigating the combinatorial approach of using hypoallergen and DNA vaccine for the treatment of tropomyosin-induced shrimp allergy [38,39 ▪▪ ]. Nucleotide sequences of MEM49 or MED171 were cloned into the mammalian expression vector pCI-Neo to construct two DNA vaccine candidates (pMEM49 and pMED171).…”

Section: Hypoallergen-encoding Dna Vaccinementioning

confidence: 99%

Emerging approaches in the diagnosis and therapy in shellfish allergy

Wai

Leung

2022

Current Opinion in Allergy &Amp; Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewDespite the high prevalence of shellfish allergy, the clinical management of seafood allergy has remained unchanged over decades. Here, we examined the current status in the diagnosis and clinical management of shellfish allergy and highlighted the imminent need for more specific diagnostic methods, as well as effective and safe therapeutic approaches for shellfish allergy.Recent findingsWith the advancement in the molecular identifications and definition of reactive epitopes of shellfish allergens, new diagnostic designs such as component-resolved diagnosis, basophil activation test (BAT) and the emerging IgE-crosslinking-induced luciferase expression are emerging. Furthermore, various allergen-specific immunotherapy strategies (such as shellfish extracts and allergens, hypoallergens, hypoallergen DNA vaccines, mimotopes and peptide-based therapies) are being explored at preclinical stages whereas limited nonallergen specific immunotherapy approaches are under clinical trials.SummaryWith an increasing understanding of the underlying immunological mechanisms and molecular features of shellfish allergy, the future for developing precise diagnostic and therapeutic strategies to better manage shellfish allergy is promising.

show abstract

“…A DNA vaccine was constructed to express a hypoallergenic form of shrimp tropomyosin (Met e 1), one major cross-reactive shellfish allergen [24]. In a murine model of shrimp tropomyosin sensitivity, therapeutic ID vaccinations with such DNA vaccine reduced allergic symptoms together with the Met e 1-specific IgE levels, intestinal Th2 cytokines expression and inflammatory cell infiltration in the jejunum.…”

Section: Recent Findings Published In the Last Two Yearsmentioning

confidence: 99%

Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy

Jacquet

2021

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewMolecular forms of allergen-specific immunotherapy (AIT) are continuously emerging to improve the efficacy of the treatment, to shorten the duration of protocols and to prevent any side effects. The present review covers the recent progress in the development of AIT based on nucleic acid encoding allergens or CpG oligodeoxynucleotides (CpG-ODN). Recent findingsTherapeutic vaccinations with plasmid deoxyribonucleic acid (DNA) encoding major shrimp Met e 1 or insect For t 2 allergen were effective for the treatment of food or insect bite allergy in respective animal models. DNA expressing hypoallergenic shrimp tropomyosin activated Foxp3 þ T regulatory (Treg) cells whereas DNA encoding For t 2 down-regulated the expression of pruritus-inducing IL-31. Coadministrations of major cat allergen Fel d 1 with high doses of CpG-ODN reduced Th2 airway inflammation through tolerance induction mediated by GATA3 þ Foxp3 hi Treg cells as well as early antiinflammatory TNF/TNFR2 signaling cascade. Non-canonical CpG-ODN derived from Cryptococcus neoformans as well as methylated CpG sites present in the genomic DNA from Bifidobacterium infantis mediated Th1 or Treg cell differentiation respectively. SummaryRecent studies on plasmid DNA encoding allergens evidenced their therapeutic potential for the treatment of food allergy and atopic dermatitis. Unmethylated or methylated CpG-ODNs were shown to activate dose-dependent Treg/Th1 responses. Large clinical trials need to be conducted to confirm these promising preclinical data. Moreover, tremendous success of messenger ribonucleic acid (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 must encourage as well the re-exploration of mRNA vaccine platform for innovative AIT.

show abstract

Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model

Cited by 15 publications

References 52 publications

Overcoming Shellfish Allergy: How Far Have We Come?

Overcoming Shellfish Allergy: How Far Have We Come?

Emerging approaches in the diagnosis and therapy in shellfish allergy

Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy

Contact Info

Product

Resources

About